Investment Thesis
Enliven Therapeutics is a pre-revenue pharmaceutical company with excellent balance sheet strength ($453.4M equity, $132.2M cash, zero debt) but burning $27.8M annually in operating losses with negative free cash flow and no revenue generation. While the company has approximately 7 years of cash runway, the fundamental absence of any revenue stream combined with high pharmaceutical development risk and unclear commercial viability makes this a speculative burn-rate play rather than an operating business.
Strengths
- Exceptional balance sheet with $453.4M stockholders' equity and zero long-term debt
- Strong liquidity position with $132.2M cash and 40.32x current ratio providing substantial runway
- Manageable annual burn rate of $19.3M FCF relative to cash position enables multi-year development timeline
Risks
- Complete absence of revenue with no clear near-term commercialization path
- Significant operating losses of $27.8M annually with negative operating cash flow
- High pharmaceutical development execution risk; clinical trial failures could accelerate cash depletion and future dilutive financing needs
- No discernible path to profitability without successful drug development and regulatory approval
Key Metrics to Watch
- Clinical trial milestones and regulatory progress on pipeline candidates
- Quarterly burn rate trend and actual cash consumption vs. projections
- Financing activities and equity dilution; need and terms of future capital raises
- Operating cash flow trend and whether burn accelerates or stabilizes
Financial Metrics
Revenue
N/A
Net Income
-23.6M
EPS (Diluted)
$-0.38
Free Cash Flow
-19.3M
Total Assets
464.9M
Cash
132.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-5.2%
ROA
-5.1%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
40.32x
Quick Ratio
40.32x
Debt/Equity
0.00x
Debt/Assets
2.5%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T09:13:34.705176 |
Data as of: 2026-03-31 |
Powered by Claude AI